Madrigal Pharmaceuticals (MDGL) pipeline and stated timing

Name in SEC filings: MADRIGAL PHARMACEUTICALS, INC.

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
resmetirom	/data readout	Stage not stated	2027	10-Q · Jul 30, 2026

Source: ORION, orionbiotechai.com/company/MDGL, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/MDGL

Nearest upcoming stated timing: resmetirom · Topline/data readout · 2027

SEC sources last checked Oct 18, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

resmetirom

Matched

Topline/data readout2027

Stage: Not stated

Public float: $5,600,000,000 · as of Jun 30, 2025 · SEC filing

We expect results from the MAESTRO-NASH OUTCOMES trial in 2027.

10-Q · Filed Jul 30, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001628280-26-050845

Alert me · Calendar: same stage and window-end month (2027-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event

Stated period and SEC wording

Disclosure in stated period

resmetiromClinical results

2027

“We expect results from the MAESTRO-NASH OUTCOMES trial in 2027.”

Filed Jul 30, 2026 · 10-Q

Period not started

The stated period has not started yet, so there is nothing to compare.

resmetiromClinical results

2027

“We expect results from the MAESTRO-NASH OUTCOMES trial in 2027.”

Filed May 6, 2026 · 10-Q

Period not started

The stated period has not started yet, so there is nothing to compare.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained company announcements

Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.

Historical catalog checked Sep 26, 2026.

No historical announcement trail is retained for this company in this catalog.

Selected registry record

Resmetirom · NCT07830758

Condition in the selected registry record: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Phase in the selected registry record: Phase 1
Identity checked: Sep 26, 2026

Original ClinicalTrials.gov record · Open the selected study

Retained company–study identity sources

Scope of retained company and registry evidence

These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.

Coverage and identity checks

Watch MDGL

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for MDGL. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See MDGL in the calendar · Review labels and methodology